...
首页> 外文期刊>Chest: The Journal of Circulation, Respiration and Related Systems >Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: A proposal to reclassify T1 lung adenocarcinoma
【24h】

Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: A proposal to reclassify T1 lung adenocarcinoma

机译:内脏胸膜浸润不影响≤2 cm肺腺癌患者的复发或总体生存:重新分类T1肺腺癌的建议

获取原文
获取原文并翻译 | 示例
           

摘要

Background: T1 (≤ 3 cm) tumors with visceral pleural invasion (VPI) are upstaged to T2a (stage IB) in the TNM classification. We investigated the effect of VPI on the cumulative incidence of recurrence (CIR) and overall survival (OS) of lung adenocarcinoma (ADC) ≤2 cm (T1a) and 2 to 3 cm (T1b). Methods: OS and CIR among patients with or without VPI were examined by tumor size (≤ 2 and 2-3 cm) in 777 patients with node-negative lung ADC ≤ 3 cm who underwent resection. Results: Among patients with tumors ≤ 2 cm, VPI was not associated with either increased CIR (P =.90) or decreased OS (P =.11). Among patients with tumors 2 to 3 cm in size, the presence of VPI was associated with increased CIR (P=.015) and decreased OS (P<.001), even after adjusting for histologic subtype. When stage I lung ADCs ≤3 cm were regrouped as either new stage IA (≤2 cm with or without VPI, 2-3 cm without VPI) or new stage IB (2-3 cm with VPI), there was a statistically significant difference in 5-year CIR and OS between new stage IA and new stage IB tumors (CIR, 18% vs 40% [P=.004]; OS, 76% vs 51% [P<.001]). Conclusions: VPI stratifies prognosis in patients with lung ADC 2 to 3 cm but not in those with tumors < 2 cm. Our proposed regrouping of a new stage IB better stratifies patients with poor prognosis, similar to published outcomes in patients with stage II disease, who may benefit from adjuvant chemotherapy.
机译:背景:在TNM分类中,具有内脏胸膜浸润(VPI)的T1(≤3 cm)肿瘤已升级为T2a(IB期)。我们调查了VPI对≤2cm(T1a)和2至3 cm(T1b)的肺腺癌(ADC)的累积复发率(CIR)和总生存期(OS)的影响。方法:对777例接受手术切除的淋巴结阴性的肺ADC≤3cm的患者的肿瘤大小(≤2和2-3 cm)进行了检查,以观察是否存在VPI的患者的OS和CIR。结果:在肿瘤≤2 cm的患者中,VPI与CIR升高(P = .90)或OS降低(P = .11)无关。在大小为2至3 cm的肿瘤患者中,即使在调整组织学亚型后,VPI的存在也与CIR升高(P = .015)和OS降低(P <.001)相关。当将≤3cm的I期肺ADC重新分组为新的IA期(≤2 cm,有或无VPI,2-3 cm,无VPI)或新的IB期(2-3 cm,有VPI),有统计学差异在IA新阶段和IB新阶段之间的5年CIR和OS中(CIR,18%vs 40%[P = .004]; OS,76%vs 51%[P <.001])。结论:VPI将肺ADC 2至3 cm的患者的预后分层,但对于肿瘤<2 cm的患者则没有。我们提议的对新的IB期进行重组可以更好地对预后较差的患者进行分层,类似于II期疾病的已发表结果,这些患者可能会从辅助化疗中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号